OrbiMed Genesis GP LLC, Director at Keros Therapeutics, Inc. (KROS), sold 250,000 shares at $44.01 ($11.0M) on 2024-08-13, disclosed to the SEC on 2024-08-15.
Open-market sale of $11.0M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.01 | 29,400 | $1.3M | 11.8% |
| 2 | $44.01 | 220,600 | $9.7M | 88.2% |
| Total | $44.01 avg | 250,000 | $11.0M | 100% |
| Filing → |
| MBX | BUY | 2025-02-19 | $2.7M | — | Filing → |
| TERN | SELL | 2024-07-17 | $562K | — | Filing → |
| IRON | BUY | 2024-06-20 | $3.0M | — | Filing → |